Jun 15, 2020
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
Jun 12, 2020
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
Jun 12, 2020
EHA25Virtual: Ruxolitinib, the First Proven Drug for Treating Steroid-refractory Acute GVHD
May 28, 2020
Cincinnati Children's HLH Research Points to Treatment for COVID-19 Cytokine Storms
May 14, 2020
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress
May 07, 2020
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
Apr 30, 2020
SAGE-217 Product Insights, 2020-2028: Mechanism of Action, Dosage & Administration, Route of Synthesis, Research & Developments, Future Market Assessments
Mar 16, 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Feb 25, 2020
Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference
Feb 03, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
Dec 09, 2019
Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting
Dec 07, 2019
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
Dec 02, 2019
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
Nov 20, 2019
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
Nov 06, 2019
Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019
Oct 01, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
Aug 16, 2019
FDA approves treatment for patients with rare bone marrow disorder
Jun 17, 2019
Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress
Jun 17, 2019
Data Presented At 24 Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients
Jun 04, 2019
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial